CHEBI ONTOLOGY - ANNOTATIONS
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/ . The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/ ). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term: MeIQx
Accession: CHEBI:76604
browse the term
Definition: An imidazoquinoxaline that is 3H-imidazo[4,5-f]quinoxaline substituted at positions 3 and 8 by methyl groups and at position 2 by an amino group. A mutagenic compound found in cooked beef.
Synonyms: exact_synonym: 3,8-dimethyl-3H-imidazo[4,5-f]quinoxalin-2-amine
related_synonym: 2-Amino-3,8-dimethyl-3H-imidazo(4,5-f)quinoxaline; 2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline; 8-MeIQX; 8-Methyl-IQX; Formula=C11H11N5; InChI=1S/C11H11N5/c1-6-5-13-7-3-4-8-10(9(7)14-6)15-11(12)16(8)2/h3-5H,1-2H3,(H2,12,15); InChIKey=DVCCCQNKIYNAKB-UHFFFAOYSA-N; SMILES=Cc1cnc2ccc3n(C)c(N)nc3c2n1
xref: Beilstein:4188271; CAS:77500-04-0; HMDB:HMDB0029864; KEGG:C19255
xref_mesh: MESH:C036990
xref: PMID:22138251; PMID:23600962; PMID:23624435; PMID:23681119; PMID:23810796; PMID:23862679; PMID:23898916; PMID:24168237; PMID:24200580; Reaxys:4188271
G
Abcb1a
ATP binding cassette subfamily B member 1A
affects transport
ISO
ABCB1A protein affects the transport of 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline
CTD
PMID:18322075
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
G
Abcc9
ATP binding cassette subfamily C member 9
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of ABCC9 mRNA
CTD
PMID:20816883
NCBI chr 4:175,531,854...175,655,849
Ensembl chr 4:175,532,547...175,655,356
G
Abcd3
ATP binding cassette subfamily D member 3
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of ABCD3 mRNA
CTD
PMID:20816883
NCBI chr 2:209,852,087...209,905,763
Ensembl chr 2:209,852,087...209,906,020
G
Abcg2
ATP binding cassette subfamily G member 2
affects transport
ISO
ABCG2 protein affects the transport of 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline
CTD
PMID:18322075
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
G
Acss1
acyl-CoA synthetase short-chain family member 1
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of ACSS1 mRNA
CTD
PMID:20816883
NCBI chr 3:139,450,383...139,500,325
Ensembl chr 3:139,450,383...139,500,325
G
Adora2b
adenosine A2B receptor
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of ADORA2B mRNA
CTD
PMID:20816883
NCBI chr10:46,940,394...46,956,772
Ensembl chr10:46,940,384...46,956,772
G
Adss2
adenylosuccinate synthase 2
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of ADSS2 mRNA
CTD
PMID:20816883
NCBI chr13:89,769,240...89,799,577
Ensembl chr13:89,769,244...89,799,604
G
Ahr
aryl hydrocarbon receptor
multiple interactions increases expression
ISO
AHR mutant form inhibits the reaction [2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of CYP1A1 mRNA]; AHR mutant form inhibits the reaction [2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of CYP1A2 mRNA] 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of AHR protein
CTD
PMID:20816883 PMID:27644595
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
G
Akt1
AKT serine/threonine kinase 1
multiple interactions
ISO
[2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline co-treated with Insulin] results in decreased phosphorylation of AKT1 protein
CTD
PMID:37005939
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
G
Akt2
AKT serine/threonine kinase 2
multiple interactions
ISO
[2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline co-treated with Insulin] results in decreased phosphorylation of AKT2 protein
CTD
PMID:37005939
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
G
Akt3
AKT serine/threonine kinase 3
multiple interactions
ISO
[2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline co-treated with Insulin] results in decreased phosphorylation of AKT3 protein
CTD
PMID:37005939
NCBI chr13:88,943,708...89,225,831
Ensembl chr13:88,946,091...89,225,708
G
Aldh3a1
aldehyde dehydrogenase 3 family, member A1
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of ALDH3A1 mRNA
CTD
PMID:20816883
NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681
G
Anln
anillin, actin binding protein
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of ANLN mRNA
CTD
PMID:20816883
NCBI chr 8:20,858,227...20,921,602
Ensembl chr 8:20,858,228...20,921,538
G
Apaf1
apoptotic peptidase activating factor 1
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of APAF1 mRNA
CTD
PMID:20816883
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
G
Arg1
arginase 1
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of ARG1 mRNA
CTD
PMID:20816883
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
G
Arnt
aryl hydrocarbon receptor nuclear translocator
affects response to substance
ISO
ARNT protein affects the susceptibility to 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline
CTD
PMID:23208499
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
G
Asap1
ArfGAP with SH3 domain, ankyrin repeat and PH domain 1
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of ASAP1 mRNA
CTD
PMID:20816883
NCBI chr 7:95,786,130...96,093,111
Ensembl chr 7:95,787,818...96,092,754
G
Atp11b
ATPase phospholipid transporting 11B (putative)
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of ATP11B mRNA
CTD
PMID:20816883
NCBI chr 2:118,585,348...118,691,076
Ensembl chr 2:118,585,342...118,690,232
G
Bax
BCL2 associated X, apoptosis regulator
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of BAX mRNA
CTD
PMID:23810796
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
G
Bcl2
BCL2, apoptosis regulator
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of BCL2 mRNA; 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of BCL2 protein
CTD
PMID:23810796
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
G
C1qtnf7
C1q and TNF related 7
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of C1QTNF7 mRNA
CTD
PMID:20816883
NCBI chr14:67,467,888...67,580,477
Ensembl chr14:67,468,014...67,580,410
G
Cacna1d
calcium voltage-gated channel subunit alpha1 D
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of CACNA1D mRNA
CTD
PMID:20816883
NCBI chr16:5,227,157...5,521,163
Ensembl chr16:5,228,306...5,668,215
G
Casp3
caspase 3
multiple interactions increases activity
ISO
[2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] results in increased activity of CASP3 protein 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased activity of CASP3 protein
CTD
PMID:20307560
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
G
Casp8
caspase 8
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of CASP8 mRNA
CTD
PMID:20816883
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
G
Ccdc47
coiled-coil domain containing 47
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of CCDC47 mRNA
CTD
PMID:20816883
NCBI chr10:91,130,303...91,148,829
Ensembl chr10:91,130,303...91,148,881
G
Ccl2
C-C motif chemokine ligand 2
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCL2 mRNA
CTD
PMID:23681119
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
G
Ccl3
C-C motif chemokine ligand 3
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCL3 mRNA
CTD
PMID:23681119
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
G
Ccl4
C-C motif chemokine ligand 4
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCL4 mRNA
CTD
PMID:23681119
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
G
Ccl7
C-C motif chemokine ligand 7
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCL7 mRNA
CTD
PMID:23681119
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
G
Ccna2
cyclin A2
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCNA2 mRNA
CTD
PMID:23681119
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
G
Ccnb1
cyclin B1
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCNB1 mRNA
CTD
PMID:23681119
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
G
Ccnb2
cyclin B2
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCNB2 mRNA
CTD
PMID:23681119
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
G
Ccnd1
cyclin D1
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCND1 mRNA
CTD
PMID:23681119
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
G
Ccne1
cyclin E1
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCNE1 mRNA
CTD
PMID:23681119
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
G
Ccr2
C-C motif chemokine receptor 2
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCR2 mRNA
CTD
PMID:23681119
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
G
Ccr7
C-C motif chemokine receptor 7
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCR7 mRNA
CTD
PMID:23681119
NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309
G
Cdc25c
cell division cycle 25C
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of CDC25C mRNA
CTD
PMID:20816883
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
G
Cdk1
cyclin-dependent kinase 1
increases expression multiple interactions
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of CDK1 mRNA [flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CDK1 mRNA
CTD
PMID:20816883 PMID:23681119
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
G
Cdk13
cyclin-dependent kinase 13
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of CDK13 mRNA
CTD
PMID:20816883
NCBI chr17:47,251,145...47,344,675
Ensembl chr17:47,251,163...47,341,721
G
Cdkn1a
cyclin-dependent kinase inhibitor 1A
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of CDKN1A mRNA; 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of CDKN1A protein
CTD
PMID:23810796
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
G
Cebpb
CCAAT/enhancer binding protein beta
increases phosphorylation affects response to substance
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased phosphorylation of CEBPB protein CEBPB protein affects the susceptibility to 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline
CTD
PMID:23208499
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
G
Cep55
centrosomal protein 55
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of CEP55 mRNA
CTD
PMID:20816883
NCBI chr 1:235,832,823...235,848,401
Ensembl chr 1:235,832,878...235,848,394
G
Cfap45
cilia and flagella associated protein 45
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of CFAP45 mRNA
CTD
PMID:20816883
NCBI chr13:84,989,474...85,012,880
Ensembl chr13:84,981,728...85,012,878
G
Cfhr4
complement factor H-related 4
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of CFHR4 mRNA
CTD
PMID:20816883
NCBI chr13:51,422,592...51,491,476
Ensembl chr13:51,422,592...51,491,502
G
Chek1
checkpoint kinase 1
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CHEK1 mRNA
CTD
PMID:23681119
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
G
Cldn14
claudin 14
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of CLDN14 mRNA
CTD
PMID:20816883
NCBI chr11:33,232,281...33,329,440
Ensembl chr11:33,232,220...33,329,171
G
Clybl
citramalyl-CoA lyase
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of CLYBL mRNA
CTD
PMID:20816883
NCBI chr15:99,283,644...99,505,697
Ensembl chr15:99,283,650...99,505,695
G
Col9a2
collagen type IX alpha 2 chain
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of COL9A2 mRNA
CTD
PMID:20816883
NCBI chr 5:134,607,616...134,624,678
Ensembl chr 5:134,607,616...134,624,677
G
Csgalnact1
chondroitin sulfate N-acetylgalactosaminyltransferase 1
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of CSGALNACT1 mRNA
CTD
PMID:20816883
NCBI chr16:20,995,210...21,330,586
Ensembl chr16:21,235,784...21,330,319
G
Cyp1a1
cytochrome P450, family 1, subfamily a, polypeptide 1
multiple interactions affects activity increases expression
ISO
[2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] results in increased expression of CYP1A1 mRNA; AHR mutant form inhibits the reaction [2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of CYP1A1 mRNA]; alpha-naphthoflavone inhibits the reaction [2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of CYP1A1 mRNA] CYP1A1 affects the activity of 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline [flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CYP1A1 mRNA
CTD
PMID:2334931 PMID:20307560 PMID:20816883 PMID:22138251 PMID:23681119 PMID:23810796 PMID:27644595 More...
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
G
Cyp1a2
cytochrome P450, family 1, subfamily a, polypeptide 2
multiple interactions decreases activity affects metabolic processing increases activity increases oxidation increases expression affects oxidation
ISO EXP
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CYP1A2 mRNA; [CYP1A2 protein co-treated with POR protein co-treated with OAT protein] results in increased susceptibility to 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline; [CYP1A2 protein results in increased metabolism of 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] which results in increased chemical synthesis of 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline metabolite; [CYP1A2 protein results in increased metabolism of 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] which results in increased chemical synthesis of 2-amino-4-hydroxymethyl-3,8-dimethylimidazo(4,5-f)quinoxaline; AHR mutant form inhibits the reaction [2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of CYP1A2 mRNA]; alpha-naphthoflavone inhibits the reaction [2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of CYP1A2 mRNA]; CYP1A2 protein results in increased hydroxylation of and results in increased activity of 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline; CYP1A2 protein results in increased metabolism of and results in increased susceptibility to 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline; xanthohumol inhibits the reaction [2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of CYP1A2 mRNA] CYP1A2 protein results in decreased activity of 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline CYP1A2 protein affects the metabolism of 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased activity of CYP1A2 protein; CYP1A2 results in increased activity of 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline CYP1A2 protein results in increased oxidation of 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline; CYP1A2 results in increased oxidation of 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of CYP1A2 mRNA; 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of CYP1A2 protein CYP1A2 affects the oxidation of 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline promotes the reaction [Carbon Tetrachloride results in decreased expression of CYP1A2 protein]; [2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline co-treated with alpha-naphthoflavone] results in increased expression of CYP1A2 protein; [2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline co-treated with beta-Naphthoflavone] results in increased expression of CYP1A2 protein; [2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline co-treated with Carbon Tetrachloride] results in increased expression of CYP1A2 mRNA; LTF protein inhibits the reaction [2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of CYP1A2 mRNA]; LTF protein inhibits the reaction [2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of CYP1A2 protein] [flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CYP1A2 mRNA; [Phenobarbital co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CYP1A2 mRNA
CTD
PMID:2334931 PMID:2655891 PMID:9202738 PMID:9581821 PMID:10503887 PMID:10503888 PMID:12079509 PMID:14965361 PMID:20192249 PMID:20307560 PMID:20448087 PMID:20816883 PMID:20930465 PMID:22118226 PMID:22138251 PMID:23681119 PMID:23810796 PMID:27644595 PMID:28160022 More...
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
G
Cyp1b1
cytochrome P450, family 1, subfamily b, polypeptide 1
increases expression multiple interactions affects response to substance
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of CYP1B1 mRNA [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CYP1B1 mRNA CYP1B1 protein affects the susceptibility to 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline
CTD
PMID:19223546 PMID:20307560 PMID:20816883
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
G
Cyp2a3
cytochrome P450, family 2, subfamily a, polypeptide 3
multiple interactions
EXP
CYP2A3 protein results in increased metabolism of and results in increased activity of 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline
CTD
PMID:8403195
NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979
G
Cyp2b3
cytochrome P450, family 2, subfamily b, polypeptide 3
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CYP2B10 mRNA
CTD
PMID:23681119
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
G
Cyp2c11
cytochrome P450, subfamily 2, polypeptide 11
increases expression
EXP
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of CYP2C11 mRNA
CTD
PMID:14965361
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
G
Cyp2c79
cytochrome P450, family 2, subfamily c, polypeptide 79
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of CYP2C8 mRNA
CTD
PMID:20816883
G
Cyp7b1
cytochrome P450 family 7 subfamily B member 1
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in decreased expression of CYP7B1 mRNA
CTD
PMID:23681119
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
G
Dapl1
death associated protein-like 1
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of DAPL1 mRNA
CTD
PMID:20816883
NCBI chr 3:43,960,993...43,980,940
Ensembl chr 3:43,960,810...43,980,940
G
Ddx42
DEAD-box helicase 42
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of DDX42 mRNA
CTD
PMID:20816883
NCBI chr10:91,148,926...91,180,940
Ensembl chr10:91,148,254...91,180,939
G
Dhrs2
dehydrogenase/reductase 2
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of DHRS2 mRNA
CTD
PMID:20816883
NCBI chr15:28,688,881...28,703,646
Ensembl chr15:28,688,940...28,703,644
G
Diaph3
diaphanous-related formin 3
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of DIAPH3 mRNA
CTD
PMID:20816883
NCBI chr15:62,543,375...63,013,060
Ensembl chr15:62,543,375...63,012,975
G
Dmxl2
Dmx-like 2
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of DMXL2 mRNA
CTD
PMID:20816883
NCBI chr 8:54,741,164...54,884,948
Ensembl chr 8:54,741,160...54,885,161
G
Duox2
dual oxidase 2
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of DUOX2 mRNA
CTD
PMID:20816883
NCBI chr 3:109,223,809...109,247,023
Ensembl chr 3:109,226,924...109,245,902
G
Dusp16
dual specificity phosphatase 16
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of DUSP16 mRNA
CTD
PMID:20816883
NCBI chr 4:167,546,780...167,630,173
Ensembl chr 4:167,548,155...167,629,980
G
E2f7
E2F transcription factor 7
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of E2F7 mRNA
CTD
PMID:20816883
NCBI chr 7:46,150,533...46,192,739
Ensembl chr 7:46,151,293...46,192,734
G
Egr1
early growth response 1
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of EGR1 mRNA
CTD
PMID:20816883
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
G
Eps8l3
EPS8 like 3
affects response to substance
ISO
EPS8L3 protein affects the susceptibility to 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline
CTD
PMID:19223546
NCBI chr 2:195,514,692...195,528,085
Ensembl chr 2:195,514,692...195,528,085
G
Ercc1
ERCC excision repair 1, endonuclease non-catalytic subunit
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of ERCC1 mRNA
CTD
PMID:22100608
NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963
G
Ercc6l
ERCC excision repair 6 like, spindle assembly checkpoint helicase
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of ERCC6L mRNA
CTD
PMID:20816883
NCBI chr X:67,245,414...67,261,222
Ensembl chr X:67,245,414...67,280,756
G
Esco2
establishment of sister chromatid cohesion N-acetyltransferase 2
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of ESCO2 mRNA
CTD
PMID:20816883
NCBI chr15:40,034,566...40,052,295
Ensembl chr15:40,034,568...40,055,306
G
Esr1
estrogen receptor 1
multiple interactions decreases activity
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline inhibits the reaction [Estradiol results in increased activity of ESR1 protein] 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased activity of ESR1 protein
CTD
PMID:16533016
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
G
Exo1
exonuclease 1
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of EXO1 mRNA
CTD
PMID:23681119
NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654
G
Fhit
fragile histidine triad diadenosine triphosphatase
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of FHIT mRNA
CTD
PMID:22100608
NCBI chr15:13,935,029...15,442,620
Ensembl chr15:13,934,995...15,442,340
G
Fos
Fos proto-oncogene, AP-1 transcription factor subunit
decreases expression multiple interactions
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of FOS mRNA [flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of FOS mRNA
CTD
PMID:20816883 PMID:23681119
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
G
Foxo1
forkhead box O1
decreases phosphorylation increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased phosphorylation of FOXO1 protein 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of FOXO1 mRNA
CTD
PMID:37005939
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
G
Fsd1
fibronectin type III and SPRY domain containing 1
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of FSD1 mRNA
CTD
PMID:20816883
NCBI chr 9:818,241...821,761
Ensembl chr 9:818,263...828,185
G
G6pc1
glucose-6-phosphatase catalytic subunit 1
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of G6PC1 mRNA
CTD
PMID:37005939
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
G
Gabpb1
GA binding protein transcription factor subunit beta 1
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of GABPB1 mRNA
CTD
PMID:20816883
NCBI chr 3:113,879,972...113,924,742
Ensembl chr 3:113,879,973...113,923,696
G
Gadd45a
growth arrest and DNA-damage-inducible, alpha
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of GADD45A mRNA
CTD
PMID:23810796
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
G
Gjc3
gap junction protein, gamma 3
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of GJC3 mRNA
CTD
PMID:20816883
NCBI chr12:16,899,846...16,912,309
Ensembl chr12:16,896,813...16,964,246
G
Gnat1
G protein subunit alpha transducin 1
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of GNAT1 mRNA
CTD
PMID:20816883
NCBI chr 8:108,350,935...108,355,671
Ensembl chr 8:108,350,935...108,355,671
G
Gnmt
glycine N-methyltransferase
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of GNMT mRNA
CTD
PMID:20816883 PMID:22100608
NCBI chr 9:14,254,675...14,258,028
Ensembl chr 9:14,254,675...14,258,434
G
Gpatch1
G patch domain containing 1
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of GPATCH1 mRNA
CTD
PMID:20816883
NCBI chr 1:87,925,606...87,974,544
Ensembl chr 1:87,925,618...87,974,544
G
Gsta1
glutathione S-transferase alpha 1
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of GSTA1 mRNA
CTD
PMID:22138251 PMID:23810796
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
G
Gstm1
glutathione S-transferase mu 1
affects response to substance
ISO
GSTM1 gene polymorphism affects the susceptibility to 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline
CTD
PMID:22564066
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
G
Gstp1
glutathione S-transferase pi 1
affects response to substance
ISO
GSTP1 protein affects the susceptibility to 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline
CTD
PMID:19223546
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
G
Gstt1
glutathione S-transferase theta 1
affects response to substance
ISO
GSTT1 gene polymorphism affects the susceptibility to 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline
CTD
PMID:22564066
NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
G
H2ax
H2A.X variant histone
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of H2AX protein modified form
CTD
PMID:28160022
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
G
H6pd
hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase)
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of H6PD mRNA
CTD
PMID:20816883
NCBI chr 5:160,434,499...160,470,203
Ensembl chr 5:160,438,697...160,470,171
G
Hipk3
homeodomain interacting protein kinase 3
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of HIPK3 mRNA
CTD
PMID:20816883
NCBI chr 3:90,796,980...90,866,701
Ensembl chr 3:90,800,296...90,867,759
G
Hmox1
heme oxygenase 1
multiple interactions increases expression
ISO
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of HMOX1 mRNA 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of HMOX1 mRNA
CTD
PMID:20307560
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
G
Hprt1
hypoxanthine phosphoribosyltransferase 1
increases mutagenesis
EXP
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased mutagenesis of HPRT1 gene
CTD
PMID:12467141
NCBI chr X:132,736,175...132,768,149
Ensembl chr X:132,736,096...132,768,154
G
Hras
HRas proto-oncogene, GTPase
increases mutagenesis
EXP
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased mutagenesis of HRAS gene
CTD
PMID:2009133
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
G
Il1b
interleukin 1 beta
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of IL1B mRNA
CTD
PMID:23681119
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
G
Il36b
interleukin 36, beta
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in decreased expression of IL36B mRNA
CTD
PMID:23681119
NCBI chr 3:7,024,881...7,030,388
Ensembl chr 3:7,021,973...7,031,619
G
Il3ra
interleukin 3 receptor subunit alpha
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of IL3RA mRNA
CTD
PMID:20816883
NCBI chr12:16,318,081...16,323,781
Ensembl chr12:16,318,081...16,323,484
G
Impg2
interphotoreceptor matrix proteoglycan 2
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of IMPG2 mRNA
CTD
PMID:20816883
NCBI chr11:44,318,836...44,418,382
Ensembl chr11:44,318,836...44,418,382
G
Incenp
inner centromere protein
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of INCENP mRNA
CTD
PMID:20816883
NCBI chr 1:206,520,655...206,550,575
Ensembl chr 1:206,523,380...206,553,265
G
Inpp5d
inositol polyphosphate-5-phosphatase D
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of INPP5D mRNA
CTD
PMID:20816883
NCBI chr 9:88,287,680...88,392,748
Ensembl chr 9:88,287,677...88,392,746
G
Jun
Jun proto-oncogene, AP-1 transcription factor subunit
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of JUN mRNA
CTD
PMID:23681119
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
G
Kcnv1
potassium voltage-gated channel modifier subfamily V member 1
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of KCNV1 mRNA
CTD
PMID:20816883
NCBI chr 7:76,260,695...76,269,170
Ensembl chr 7:76,260,695...76,269,170
G
Kctd2
potassium channel tetramerization domain containing 2
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of KCTD2 mRNA
CTD
PMID:20816883
NCBI chr10:100,663,013...100,674,756
Ensembl chr10:100,662,884...100,674,336
G
Kif1b
kinesin family member 1B
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of KIF1B mRNA
CTD
PMID:20816883
NCBI chr 5:159,607,697...159,742,778
Ensembl chr 5:159,561,271...159,742,778
G
Kifc1
kinesin family member C1
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of KIFC1 mRNA
CTD
PMID:20816883
NCBI chr20:4,998,832...5,017,107
Ensembl chr20:4,999,047...5,017,105
G
Klf1
KLF transcription factor 1
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of KLF1 mRNA
CTD
PMID:20816883
NCBI chr19:23,250,627...23,253,802
Ensembl chr19:23,250,631...23,253,758
G
Klf6
KLF transcription factor 6
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of KLF6 mRNA
CTD
PMID:20816883
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
G
Knl1
kinetochore scaffold 1
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of KNL1 mRNA
CTD
PMID:20816883
NCBI chr 3:106,029,627...106,091,915
Ensembl chr 3:106,029,661...106,091,915
G
Kras
KRAS proto-oncogene, GTPase
increases mutagenesis
EXP
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased mutagenesis of KRAS gene
CTD
PMID:18271921
NCBI chr 4:178,185,418...178,218,484
G
Lama1
laminin subunit alpha 1
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of LAMA1 mRNA
CTD
PMID:20816883
NCBI chr 9:107,692,770...107,816,847
Ensembl chr 9:107,692,770...107,817,478
G
Lif
LIF, interleukin 6 family cytokine
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of LIF mRNA
CTD
PMID:20816883
NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482
G
Lrrc58
leucine rich repeat containing 58
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of LRRC58 mRNA
CTD
PMID:20816883
NCBI chr11:62,850,507...62,862,829
Ensembl chr11:62,847,562...62,862,829
G
Ltf
lactotransferrin
multiple interactions
EXP
LTF protein inhibits the reaction [2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of CYP1A2 mRNA]; LTF protein inhibits the reaction [2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of CYP1A2 protein]
CTD
PMID:12079509
NCBI chr 8:110,999,948...111,022,795
Ensembl chr 8:110,999,948...111,022,795
G
Mat2a
methionine adenosyltransferase 2A
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of MAT2A mRNA
CTD
PMID:20816883
NCBI chr 4:104,489,877...104,495,447
Ensembl chr 4:104,488,466...104,495,493
G
Mki67
marker of proliferation Ki-67
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of MKI67 mRNA
CTD
PMID:20816883
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
G
Mt-cyb
mitochondrially encoded cytochrome b
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of CYTB mRNA
CTD
PMID:20816883
NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278
Ensembl chr MT:14,136...15,278
G
Nat2
N-acetyltransferase 2
multiple interactions increases response to substance increases acetylation affects activity
ISO EXP
[2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline affects the activity of NAT2 polymorphism] which affects the chemical synthesis of Glucose; [CYP3A7 co-treated with NAT2] results in increased susceptibility to 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline; [xanthohumol co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of NAT2 mRNA; NAT2 protein results in increased metabolism of and results in increased susceptibility to 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline [Phenobarbital co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in decreased expression of NAT2 mRNA NAT2 protein results in increased susceptibility to 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline NAT2 protein results in increased acetylation of 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline
CTD
PMID:7625840 PMID:19666988 PMID:22138251 PMID:23681119 PMID:28160022 PMID:37423373 More...
NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520
G
Nek2
NIMA-related kinase 2
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of NEK2 mRNA
CTD
PMID:20816883
NCBI chr13:103,405,818...103,419,063
Ensembl chr13:103,405,819...103,419,051
G
Nfe2l2
NFE2 like bZIP transcription factor 2
increases expression multiple interactions
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of NFE2L2 mRNA [2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] results in increased expression of NFE2L2 mRNA
CTD
PMID:20307560
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
G
Nfkb2
nuclear factor kappa B subunit 2
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of NFKB2 mRNA
CTD
PMID:23681119
NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213
G
Nmu
neuromedin U
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of NMU mRNA
CTD
PMID:20816883
NCBI chr14:31,844,564...31,872,196
Ensembl chr14:31,844,728...31,872,192
G
Nr0b2
nuclear receptor subfamily 0, group B, member 2
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of NR0B2 mRNA
CTD
PMID:20816883
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
G
Oat
ornithine aminotransferase
multiple interactions
ISO
[CYP1A2 protein co-treated with POR protein co-treated with OAT protein] results in increased susceptibility to 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline
CTD
PMID:9581821 PMID:10503888
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
G
Orc1
origin recognition complex, subunit 1
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of ORC1 mRNA
CTD
PMID:20816883
NCBI chr 5:123,324,273...123,348,375
Ensembl chr 5:123,324,315...123,348,375
G
Pck1
phosphoenolpyruvate carboxykinase 1
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of PCK1 mRNA
CTD
PMID:37005939
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
G
Pdzd7
PDZ domain containing 7
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of PDZD7 mRNA
CTD
PMID:20816883
NCBI chr 1:243,888,295...243,907,778
Ensembl chr 1:243,888,281...243,906,839
G
Pgm5
phosphoglucomutase 5
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of PGM5 mRNA
CTD
PMID:20816883
NCBI chr 1:222,325,638...222,513,434
Ensembl chr 1:222,325,643...222,513,437
G
Pim2
Pim-2 proto-oncogene, serine/threonine kinase
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of PIM2 mRNA
CTD
PMID:22100608
NCBI chr X:14,617,582...14,622,851
Ensembl chr X:14,617,582...14,622,851
G
Pip5kl1
phosphatidylinositol-4-phosphate 5-kinase-like 1
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of PIP5KL1 mRNA
CTD
PMID:20816883
NCBI chr 3:15,860,493...15,869,264
Ensembl chr 3:15,855,946...15,869,165
G
Por
cytochrome p450 oxidoreductase
multiple interactions
ISO
[CYP1A2 protein co-treated with POR protein co-treated with OAT protein] results in increased susceptibility to 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline
CTD
PMID:9581821 PMID:10503888
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
G
Poted
POTE ankyrin domain family member D
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of POTED mRNA
CTD
PMID:20816883
NCBI chr17:57,942,124...57,975,149
Ensembl chr17:57,942,162...57,975,654
G
Ppara
peroxisome proliferator activated receptor alpha
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of PPARA mRNA
CTD
PMID:37005939
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
G
Ppargc1a
PPARG coactivator 1 alpha
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of PPARGC1A mRNA
CTD
PMID:37005939
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
G
Prss21
serine protease 21
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of PRSS21 mRNA
CTD
PMID:20816883
NCBI chr10:12,899,820...12,905,612
Ensembl chr10:12,900,535...12,905,618
G
Ptgs1
prostaglandin-endoperoxide synthase 1
increases metabolic processing
ISO
PTGS1 protein results in increased metabolism of 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline
CTD
PMID:11159734
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
G
Ptgs2
prostaglandin-endoperoxide synthase 2
increases metabolic processing
ISO
PTGS2 protein results in increased metabolism of 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline
CTD
PMID:11159734
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
G
Rab7b
Rab7b, member RAS oncogene family
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of RAB7B mRNA
CTD
PMID:20816883
NCBI chr13:43,121,168...43,147,581
Ensembl chr13:43,121,226...43,147,581
G
Rad18
RAD18 E3 ubiquitin protein ligase
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of RAD18 mRNA
CTD
PMID:23681119
NCBI chr 4:145,735,654...145,821,102
Ensembl chr 4:145,735,654...145,821,069
G
Rad23b
RAD23 homolog B, nucleotide excision repair protein
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of RAD23B mRNA
CTD
PMID:20816883
NCBI chr 5:70,090,232...70,128,340
Ensembl chr 5:70,090,232...70,128,319
G
Rad51
RAD51 recombinase
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of RAD51 mRNA
CTD
PMID:23681119
NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
G
Rad51ap1
RAD51 associated protein 1
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of RAD51AP1 mRNA
CTD
PMID:20816883
NCBI chr 4:159,759,454...159,772,473
Ensembl chr 4:159,759,459...159,772,524
G
Rad54l
RAD54 like
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of RAD54L mRNA
CTD
PMID:20816883
NCBI chr 5:129,575,431...129,605,100
Ensembl chr 5:129,575,378...129,605,070
G
Rapgef1
Rap guanine nucleotide exchange factor 1
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of RAPGEF1 mRNA
CTD
PMID:20816883
NCBI chr 3:12,898,349...13,016,234
Ensembl chr 3:12,898,266...13,013,984
G
Rbbp6
RB binding protein 6, ubiquitin ligase
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of RBBP6 mRNA
CTD
PMID:20816883
NCBI chr 1:177,503,988...177,537,397
Ensembl chr 1:177,503,313...177,535,678
G
Rnf125
ring finger protein 125
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of RNF125 mRNA
CTD
PMID:20816883
NCBI chr18:12,254,066...12,275,719
Ensembl chr18:12,253,852...12,275,983
G
Rnf186
ring finger protein 186
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of RNF186 mRNA
CTD
PMID:20816883
NCBI chr 5:151,210,492...151,211,716
Ensembl chr 5:151,210,492...151,211,716
G
Rps6ka5
ribosomal protein S6 kinase A5
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of RPS6KA5 mRNA
CTD
PMID:20816883
NCBI chr 6:119,828,823...120,006,190
Ensembl chr 6:119,828,846...120,006,224
G
Rrm2
ribonucleotide reductase regulatory subunit M2
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of RRM2 mRNA
CTD
PMID:20816883
NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
G
S100a2
S100 calcium binding protein A2
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of S100A2 mRNA
CTD
PMID:20816883
NCBI chr 2:176,077,081...176,078,325
G
Serpini2
serpin family I member 2
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of SERPINI2 mRNA
CTD
PMID:20816883
NCBI chr 2:160,014,721...160,044,271
Ensembl chr 2:160,014,721...160,044,280
G
Shcbp1
SHC binding and spindle associated 1
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of SHCBP1 mRNA
CTD
PMID:20816883
NCBI chr16:84,672,277...84,703,843
Ensembl chr16:84,672,321...84,703,844
G
Slc15a1
solute carrier family 15 member 1
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of SLC15A1 mRNA
CTD
PMID:20816883
NCBI chr15:98,537,641...98,582,544
Ensembl chr15:98,537,641...98,582,545
G
Slc22a2
solute carrier family 22 member 2
multiple interactions decreases activity
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline inhibits the reaction [SLC22A2 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide] 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased activity of SLC22A2 protein
CTD
PMID:30189235
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
G
Slc22a3
solute carrier family 22 member 3
multiple interactions decreases activity
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline inhibits the reaction [SLC22A3 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide] 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased activity of SLC22A3 protein
CTD
PMID:30189235
NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
G
Slc7a11
solute carrier family 7 member 11
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of SLC7A11 mRNA
CTD
PMID:20816883
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
G
Smyd3
SET and MYND domain containing 3
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of SMYD3 mRNA
CTD
PMID:22100608
NCBI chr13:90,709,263...91,266,209
Ensembl chr13:90,709,270...91,266,253
G
Tas2r120
taste receptor, type 2, member 120
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of TAS2R20 mRNA
CTD
PMID:20816883
NCBI chr 4:165,952,266...165,953,153
Ensembl chr 4:165,952,266...165,953,153
G
Tbc1d25
TBC1 domain family, member 25
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of TBC1D25 mRNA
CTD
PMID:20816883
NCBI chr X:14,314,095...14,339,171
Ensembl chr X:14,314,414...14,338,275
G
Tnf
tumor necrosis factor
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of TNF mRNA
CTD
PMID:23681119
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
G
Tnfsf9
TNF superfamily member 9
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of TNFSF9 mRNA
CTD
PMID:20816883
NCBI chr 9:1,944,017...1,946,351
Ensembl chr 9:1,944,017...1,946,345
G
Top2a
DNA topoisomerase II alpha
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of TOP2A mRNA
CTD
PMID:20816883
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
G
Tp53
tumor protein p53
increases mutagenesis increases expression
EXP ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased mutagenesis of TP53 gene 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of TP53 protein
CTD
PMID:8844820 PMID:23810796
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
G
Trappc9
trafficking protein particle complex subunit 9
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of TRAPPC9 mRNA
CTD
PMID:22100608
NCBI chr 7:104,521,593...104,998,352
Ensembl chr 7:104,521,593...104,998,352
G
Trim63
tripartite motif containing 63
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of TRIM63 mRNA
CTD
PMID:20816883
NCBI chr 5:146,533,492...146,547,332
Ensembl chr 5:146,533,507...146,547,322
G
Trim72
tripartite motif containing 72
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of TRIM72 mRNA
CTD
PMID:20816883
NCBI chr 1:182,613,753...182,621,613
Ensembl chr 1:182,613,712...182,621,606
G
Ube2j2
ubiquitin-conjugating enzyme E2, J2
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of UBE2J2 mRNA
CTD
PMID:20816883
NCBI chr 5:166,533,374...166,547,811
Ensembl chr 5:166,533,418...166,547,804
G
Ugt1a1
UDP glucuronosyltransferase family 1 member A1
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of UGT1A1 mRNA
CTD
PMID:22138251 PMID:23810796
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
G
Ugt1a2
UDP glucuronosyltransferase 1 family, polypeptide A2
multiple interactions
ISO
[xanthohumol co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of UGT1A2 mRNA
CTD
PMID:22138251
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
G
Ugt2b1
UDP glucuronosyltransferase 2 family, polypeptide B1
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in decreased expression of UGT2B1 mRNA
CTD
PMID:23681119
NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986
G
Uhrf1
ubiquitin-like with PHD and ring finger domains 1
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of UHRF1 mRNA
CTD
PMID:20816883
NCBI chr 9:1,133,117...1,154,639
Ensembl chr 9:1,134,909...1,154,631
G
Vamp1
vesicle-associated membrane protein 1
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of VAMP1 mRNA
CTD
PMID:20816883
NCBI chr 4:158,012,634...158,019,350
Ensembl chr 4:158,012,663...158,019,349
G
Vil1
villin 1
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of VIL1 mRNA
CTD
PMID:20816883
NCBI chr 9:75,991,141...76,018,860
Ensembl chr 9:75,991,141...76,018,858
G
Wasl
WASP like actin nucleation promoting factor
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of WASL mRNA
CTD
PMID:20816883
NCBI chr 4:53,083,536...53,132,061
Ensembl chr 4:53,083,536...53,132,022
G
Yap1
Yes1 associated transcriptional regulator
decreases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of YAP1 mRNA
CTD
PMID:20816883
NCBI chr 8:5,095,705...5,166,808
Ensembl chr 8:5,095,722...5,167,010
G
Zfp799
zinc finger protein 799
increases expression
ISO
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in increased expression of ZNF799 mRNA
CTD
PMID:20816883
NCBI chr 7:11,894,224...11,910,809
Ensembl chr 7:11,898,149...11,910,798
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all